SPDR S&P Biotech (XBI) 64.00 $XBI Downtrend Call Working

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
SPDR S&P Biotech (XBI) 64.00 $XBI

Downtrend Call Working As SPDR S&P Biotech ETF Stock Falls 9.0% (XBI)
Comtex SmarTrend(R) - Thu Oct 22, 9:43AM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on September 25th, 2015 at $69.95. In approximately 4 weeks, SPDR S&P Biotech ETF has returned 9.01% as of today's recent price of $63.65.
XBI: 64.00 (-0.33)

Shareholder Alert: 4 Stocks Ready to Make a Move
ACCESSWIRE - Mon Oct 19, 11:17AM CDT
WINDSOR, ONTARIO / ACCESSWIRE / October 19, 2015 / The Wealthy Biotech Trader (or "WBT", an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma, medical device and general healthcare stocks making news and subsequent market moves, is alerting traders about several trade ideas within the very healthy medical device sector.
LOXO: 23.25 (-0.35), XBI: 64.00 (-0.33), FORD: 1.19 (+0.01)

Watch for SPDR S&P Biotech ETF to Potentially Rebound After Falling 4.41% Yesterday
Comtex SmarTrend(R) - Tue Oct 13, 4:00PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $61.16 to a high of $65.20. Yesterday, the shares fell 4.4%, which took the trading range below the 3-day low of $61.38 on volume of 5.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
XBI: 64.00 (-0.33)

SPDR S&P Biotech ETF Down 7.4% Since SmarTrend Downtrend Call (XBI)
Comtex SmarTrend(R) - Tue Oct 13, 11:54AM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on September 25th, 2015 at $69.95. In approximately 3 weeks, SPDR S&P Biotech ETF has returned 7.38% as of today's recent price of $64.79.
XBI: 64.00 (-0.33)

Zacks Investment Ideas feature highlights: iShares Nasdaq Biotechnology, SPDR S&P Biotech ETF, ProShares Short S&P500, ProShares UltraShort S&P500 and ProShares UltraPro Short S&P500
Zacks Equity Research - Zacks Investment Research - Mon Oct 12, 8:30AM CDT
Zacks Investment Ideas feature highlights: iShares Nasdaq Biotechnology, SPDR S&P Biotech ETF, ProShares Short S&P500, ProShares UltraShort S&P500 and ProShares UltraPro Short S&P500
SPXU: 32.52 (-1.69), SH: 21.00 (-0.36), SDS: 20.21 (-0.71), XBI: 64.00 (-0.33), IBB: 303.53 (-0.93)

Protea: A High Quality Small-Cap to Ride Out Biotech's Drop
ACCESSWIRE - Mon Oct 12, 8:16AM CDT
REDONDO BEACH, CA / ACCESSWIRE / October 12, 2015 / The SPDR S&P Biotech ETF (ARCA: XBI) has fallen more than 20% over the past three months, which significantly outpaced the S&P 500's 4.7% fall over the same timeframe. With the House of Representatives subpoenaing Valeant Pharmaceuticals International Inc. (NYSE: VRX) for documents related to drug price increases, the market is concerned that the federal government may be stepping up its efforts to curb increases in drug prices.
VRX: 99.12 (-19.49), FMI: 21.98 (-0.09), XBI: 64.00 (-0.33), WAT: 122.87 (+1.53), VRX.TO: 129.66 (-24.55)

Juno Therapeutics (JUNO) Stock Could Lead the Way to a Biotech Bounce
at The Street - Fri Oct 09, 10:40AM CDT
We're watching the SPDR S&P Biotech ETF and its components for clues to a rally. Rejected lows in the charts have been encouraging.
XBI: 64.00 (-0.33), JUNO: 48.38 (+1.69)

Charting a Biotech Bounce
at The Street - Fri Oct 09, 10:10AM CDT
We're watching the SPDR S&P Biotech ETF for clues to a rally. Rejected lows in the charts have been encouraging.
XBI: 64.00 (-0.33), JUNO: 48.38 (+1.69)

7 Huge Mistakes Every ETF Investor Needs to Avoid
Eric Dutram - Zacks Investment Research - Fri Oct 09, 9:45AM CDT
These are some of the most common misconceptions about ETF investing, make sure you do not make the same mistakes!
SPY: 205.14 (+3.29), VXX: 18.80 (-1.49), GLD: 111.71 (-0.02), XBI: 64.00 (-0.33), IBB: 303.53 (-0.93), IAU: 11.27 (unch)

Correction in Health Care Stocks Remains in Full Force
at The Street - Thu Oct 08, 3:00PM CDT
Have we reached the point where something will be done about it?
CI: 131.09 (-5.52), ANTM: 137.98 (-4.81), HCA: 64.93 (-6.27), XBI: 64.00 (-0.33), UNH: 111.92 (-6.19), IBB: 303.53 (-0.93), XLV: 67.66 (-0.63)

3 Large-Cap Biotech Stocks Whose Valuations Should Make You Skeptical
Sean Williams, The Motley Fool - Motley Fool - Wed Oct 07, 7:03AM CDT
Source: Federal Reserve Bank of New York. With the exception of the last couple of weeks, the biotech sector has been a vast outperformer since the Great Recession. The broad-based S&P 500 has pretty much tripled since hitting its lows in...
BIIB: 278.88 (+2.54), VRTX: 108.85 (-0.77), XBI: 64.00 (-0.33), INCY: 107.94 (+0.79)

SPDR S&P Biotech ETF Rises 4.89% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Oct 02, 4:07PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $60.45 to a high of $65.75. Yesterday, the shares gained 4.9%, which took the trading range above the 3-day high of $64.56 on volume of 9.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XBI: 64.00 (-0.33)

Biotech ETFs Looking Attractive After Sell-Off
Sweta Killa - Zacks Investment Research - Thu Oct 01, 7:55AM CDT
The current slide in biotech sector made the stocks valuation attractive at the current levels.
BBP: 28.90 (+0.08), SBIO: 27.73 (-0.34), XBI: 64.00 (-0.33), IBB: 303.53 (-0.93)

Top ETF Stories of September
Zacks Equity Research - Zacks Investment Research - Wed Sep 30, 12:34PM CDT
Inside the top financial stories of September and their impact on the world of ETFs.
D: 74.81 (+0.89), KRE: 42.32 (+0.90), BBC: 26.48 (-0.36), SBIO: 27.73 (-0.34), VRX: 99.12 (-19.49), EWG: 26.83 (+0.50), IAI: 39.93 (+1.03), REM: 10.30 (+0.05), XBI: 64.00 (-0.33), EDV: 120.11 (+0.85), IBB: 303.53 (-0.93), GDX: 16.17 (+0.32)

Notable ETF Inflow Detected - XBI, ZIOP, ACHN, ZFGN
ETFChannel.com - Wed Sep 30, 9:52AM CDT
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF where we have detected an approximate $186.0 million dollar inflow -- that's a 10.1% increase...
XBI: 64.00 (-0.33)

Look for Shares of SPDR S&P Biotech ETF to Potentially Rebound after Yesterday's 7.19% Sell Off
Comtex SmarTrend(R) - Mon Sep 28, 4:09PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $61.28 to a high of $67.06. Yesterday, the shares fell 7.2%, which took the trading range below the 3-day low of $65.98 on volume of 14.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
XBI: 64.00 (-0.33)

Drug Pricing Fears Erase Biotech Stock Gains for the Year
at The Street - Mon Sep 28, 12:33PM CDT
The bloodletting in biotech stocks continued Monday with aggressive selling erasing the year's gains in a key sector exchange-traded fund. Another closely-followed ETF is barely hanging on to its outperformance.
BIIB: 278.88 (+2.54), VRX: 99.12 (-19.49), XBI: 64.00 (-0.33), IBB: 303.53 (-0.93)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Koning Vera Breast CT Gains Canada License for 3D Imaging

Updated Category News Views 0

Shake-up in Breast Imaging: Koning Vera Gains Canadian Nod Alright, folks, game-changer alert in the breast imaging arena! Koning Health is shaking things up north of the border. The Koning Vera Breast CT system just snagged that coveted Medical Device License (MDL) from Health Canada, clearing the path for Canadian healthcare providers to use this tech marvel. And, let...

Continue Reading
TrewUp Scores Another Inc. Power Partner Award Win

Updated Category News Views 1

Breaking Through the Noise in B2B Nobody today would be shocked to hear business owners are practically drowning in options when it comes to B2B service providers. But amid this noisy sea, TrewUp has managed to shout louder than the rest by grabbing a 2026 Inc. Power Partner Awards win—for the second year in a row, no less. It seems like they’ve cracked some sort of...

Continue Reading
Winter Prep: Home Safety Vital for Older Adults

Updated Category News Views 2

Cold Weather is All About Precaution It ain't the first day at the fair when you realize winter's sneaking up, and with it, the looming concern of older family members hunkering down indoors. Executive Home Care's calling out, saying it straight: if you've got seniors in your midst, now's the time to batten down the hatches. The winter months can turn into a slippery...

Continue Reading
New CEO at Simpli.fi: Sean McCaffrey Takes Charge

Updated Category News Views 9

A New Captain at Simpli.fi's Helm In the fast-paced world of digital advertising, Simpli.fi isn't just sitting on the sidelines. They've gone and snagged Sean McCaffrey as their new CEO. Now, for those who remember GSTV's rise to 30,000 locations under McCaffrey, this appointment carries some serious weight. McCaffrey's Track Record: Setting the Pace McCaffrey's no...

Continue Reading
Jackson Hewitt Aims to Recruit 15,000 Seasonal Staff

Updated Category News Views 6

Revving Up for Tax Season: Jackson Hewitt's Hiring Push When tax season looms, the hustle can't be understated, and Jackson Hewitt is cranking it up by hunting for 15,000 new recruits to tackle this annual financial circus. Starting October 26, this hiring fest is open season across the nation, pulling out all the stops to bolster its workforce. But what does this mean...

Continue Reading
University of Phoenix Lowers Costs for Transfer Students

Updated Category News Views 3

The Pocket-Saving Game of Transfer Credits Here's the buzz: the University of Phoenix is putting some serious coin back into students' pockets through transfer credits. We're looking at more than $12,010 in savings per student, thanks to these policies, which is no chump change by any stretch. As over 900,000 credits were tossed into the pot, the savings side of education...

Continue Reading
Freight Rebound Sparks Strategic M&A Opportunities

Updated Category News Views 3

Is the Freight Recovery Here to Stay? Just when you thought trucking might have run out of gas, we're hitting a sharp turn back into growth town. For those of you dropping equity crumbs every which way but loose in the last few years, this freight lull has been brutal—like the hangover from hell. But Brown Gibbons Lang & Company’s fresh report now hints at a brighter...

Continue Reading
AEP Boosts Dividend Amid $78 Billion Expansion Plan

Updated Category News Views 5

Dividend Hike Sets the Stage Kicking things off with a neat little surprise, American Electric Power (NASDAQ:AEP) has decided to fatten up that dividend check to 97 cents per share—or a solid 2-cent bump. Now, that might not have you dancing on the trading floor, but it sure shows us that AEP's got intentions worth watching. We're looking at a December 10 payday, so...

Continue Reading
DARPA Pumps $10.7M into RxMP's Hemorrhage Control Drug

Updated Category News Views 2

RxMP Therapeutics Lands a DARPA Deal Would you look at that—RxMP Therapeutics just got handed a load of cash thanks to some good old government backing. Up to $10.7 million from DARPA is no chump change. It's like finding a lifeboat right when you're treading water out there in the big bad sea. This award under the RAPIID program is set to move the needle for RxMP’s...

Continue Reading
IBM Backs Leena AI: Shaping Enterprise Automation

Updated Category News Views 9

IBM's Strategic Bet on Enterprise Automation Diving into the blazing 2026 market, IBM Ventures has thrown its weight behind Leena AI, an enterprise agentic AI firm that's out to shake things up. You see, the name of the game isn't just flashy AI chatbots anymore. Companies like Leena AI are setting their sights on the back-office grunt work—the lifeblood operations in...

Continue Reading

Top 5 Most Recently Viewed Articles

Terra Balcanica Secures Financing for Growth and Expansion

Updated Category News Views 180

Terra Balcanica's Successful Financing Initiative With great enthusiasm, Terra Balcanica Resources Corp. (“Terra”) (CNSX: TERA; Frankfurt: UB1) has finalized the first tranche of a significant private placement financing. This strategic move yielded gross proceeds of $129,000 Canadian, showcasing the trust that investors place in the company’s vision and potential....

Continue Reading
Bruce Pon Joins the Foundation for New Creative Economies Board

Updated Category News Views 114

Bruce Pon Appointed to the Board of FNC? The Foundation for New Creative Economies (FNC?) is excited to announce the appointment of Bruce Pon as a new board member. This significant change occurs as Marjorie Hernandez, a key figure in the LUKSO ecosystem, transitions off the board after her dedicated service. FNC? focuses on fostering innovation and growth within the...

Continue Reading
Fast-Casual Showdown: Sweetgreen and Cava's Q2 Earnings

Updated Category News Views 218

Sweetgreen vs. Cava: A Tale of Two Earnings Reports The fast-casual restaurant sector is experiencing an intense rivalry as Sweetgreen Inc (SG) and Cava Group Inc (CAVA) share their second quarter financial results. Each company has a distinct narrative, with Sweetgreen facing significant challenges while Cava seems ready to thrive. Sweetgreen's Recent Struggles...

Continue Reading
PainReform Unveils Innovative Ocular Drug-Delivery System

Updated Category News Views 174

PainReform's Breakthrough in Ocular Drug Delivery PainReform Ltd. (Nasdaq: PRFX) has made exciting strides in the world of ocular therapeutics. The company's recent research and development assessment highlights its innovative LayerBio platform's capacity to deliver drugs effectively without the cumbersome use of eye drops. This technology aims to transform the...

Continue Reading
Park Aerospace Reports Impressive Q3 Fiscal Performance

Updated Category News Views 101

Overview of Financial Results Park Aerospace Corp. (NYSE: PKE) has recently announced significant financial results for the fiscal year third quarter, showcasing resilience and growth despite various challenges faced in recent times. As a key player in the aerospace materials sector, Park continues to demonstrate its ability to drive sales and maintain profitability....

Continue Reading